Header Logo

Connection

Shabir Madhi to Immunization Schedule

This is a "connection" page, showing publications Shabir Madhi has written about Immunization Schedule.
Connection Strength

6,830
  1. Serotype-specific serum immunoglobulin G at 18 months of age following one or two doses of a primary series of 10-valent or 13-valent pneumococcal conjugate vaccine and a booster dose at nine months of age: a randomized controlled study. Expert Rev Vaccines. 2025 Dec; 24(1):121-127.
    View in: PubMed
    Score: 0,920
  2. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial. Lancet Infect Dis. 2020 12; 20(12):1426-1436.
    View in: PubMed
    Score: 0,677
  3. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa. Vaccine. 2020 02 28; 38(10):2350-2360.
    View in: PubMed
    Score: 0,652
  4. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children. J Infect Dis. 2019 09 26; 220(9):1529-1538.
    View in: PubMed
    Score: 0,636
  5. Immunogenicity of a combined schedule of trivalent oral and inactivated polio vaccines in South African infants. Expert Rev Vaccines. 2019 07; 18(7):751-754.
    View in: PubMed
    Score: 0,623
  6. Antibody persistence in pre-school children after hexavalent vaccine infant primary and booster administration. Hum Vaccin Immunother. 2019; 15(3):658-668.
    View in: PubMed
    Score: 0,608
  7. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial. Expert Rev Vaccines. 2017 06; 16(6):641-656.
    View in: PubMed
    Score: 0,541
  8. Single priming and a booster dose of 10-valent and 13-valent pneumococcal conjugate vaccine (PCV) maintains suppression of vaccine serotype colonization in South African children at 3, 4, and 5 years of age: a single-centre, open-labelled, randomized trial. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):1011-1019.
    View in: PubMed
    Score: 0,226
  9. Vaccination of the HIV-1 infected child. SADJ. 2001 Dec; 56(12):610-3.
    View in: PubMed
    Score: 0,185
  10. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
    View in: PubMed
    Score: 0,175
  11. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials. Expert Rev Vaccines. 2020 12; 19(12):1177-1189.
    View in: PubMed
    Score: 0,173
  12. Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis. Influenza Other Respir Viruses. 2019 09; 13(5):438-452.
    View in: PubMed
    Score: 0,156
  13. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy. Clin Infect Dis. 2017 Nov 13; 65(11):1897-1904.
    View in: PubMed
    Score: 0,140
  14. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial. Lancet Infect Dis. 2016 08; 16(8):923-34.
    View in: PubMed
    Score: 0,125
  15. The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience. Hum Vaccin Immunother. 2016; 12(2):314-25.
    View in: PubMed
    Score: 0,123
  16. Temporal changes in pneumococcal colonization in a rural African community with high HIV prevalence following routine infant pneumococcal immunization. Pediatr Infect Dis J. 2013 Nov; 32(11):1270-8.
    View in: PubMed
    Score: 0,106
  17. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Pediatr Infect Dis J. 2013 Aug; 32(8):889-97.
    View in: PubMed
    Score: 0,104
  18. Review of a new fully liquid, hexavalent vaccine: Hexaxim. Expert Opin Biol Ther. 2013 Apr; 13(4):575-93.
    View in: PubMed
    Score: 0,101
  19. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T vaccine (Pentaxim) given at 18 - 19 months of age in South African children primed at 6, 10 and 14 weeks of age with the same vaccine. S Afr Med J. 2011 Nov 28; 101(12):879-83.
    View in: PubMed
    Score: 0,092
  20. The National Advisory Group on Immunization (NAGI) of the Republic of South Africa. Vaccine. 2010 Apr 19; 28 Suppl 1:A31-4.
    View in: PubMed
    Score: 0,083
  21. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. J Infect Dis. 2009 Apr 15; 199(8):1168-76.
    View in: PubMed
    Score: 0,077
  22. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. Pediatr Infect Dis J. 2005 May; 24(5):410-6.
    View in: PubMed
    Score: 0,059
  23. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa. Hum Vaccin Immunother. 2021 06 03; 17(6):1770-1778.
    View in: PubMed
    Score: 0,043
  24. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 02; 7(2):e91-e103.
    View in: PubMed
    Score: 0,040
  25. Measles seroprevalence in pregnant women in Soweto, South Africa: a nested cohort study. Clin Microbiol Infect. 2020 Apr; 26(4):515.e1-515.e4.
    View in: PubMed
    Score: 0,040
  26. Pneumococcal conjugate vaccine--prospects for intervention in children. Semin Respir Infect. 1999 Sep; 14(3):285-94.
    View in: PubMed
    Score: 0,040
  27. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015 Jul 17; 29(11):1345-54.
    View in: PubMed
    Score: 0,030
  28. A DTaP-IPV//PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines. 2011 Jul; 10(7):981-1005.
    View in: PubMed
    Score: 0,022
  29. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009 May; 28(5):365-71.
    View in: PubMed
    Score: 0,019
  30. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ. 2006 Oct; 84(10):811-8.
    View in: PubMed
    Score: 0,016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.